Hank Safferstein, Generian CEO
June 29, 2022 07:00 AM EDT
Deals
R&D

Astel­las sub­sidiary to part­ner with Pitts­burgh up­start in search for 'un­drug­gable' pro­teins

Tyler Patchen

News Reporter

As Astel­las con­tin­ues its dri­ve to build out its gene ther­a­py port­fo­lio and ca­pa­bil­i­ties, a sub­sidiary of the Japan­ese phar­ma com­pa­ny has en­tered in­to a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times